Public Accounts committee  I'll start. I'll just go back to the context that is so important here. It's so important because it's easy today, literally three years after the pandemic started, to think out of context about the terms and conditions that were negotiated. I say this because it's so important.

Public Accounts committee  I've already said what I have to say about this. I agree that we're not going to settle this issue this evening and that we should discuss it with our internal teams. I agree with what my colleagues said. If there are any specific matters that we need to discuss to help us understand…

Public Accounts committee  I'll start. I think your question around the precedent is a really good one and one not to take lightly, because there is Canada and there are many other countries in the world. Leaks have happened. Again, the precedent you just raised is a very valid concern globally, so I think that's one piece.

Public Accounts committee  Again, not to negotiate here—I think we have teams who are more capable of doing that than us here tonight—but considering terms and conditions to uphold the safeguards around confidentiality would be really important, such as non-disclosure commitments, as an example. Non-disclosure agreements and things like that could potentially....

Public Accounts committee  These agreements are very long and complex. They have been amended a few times, because situations have evolved. We've had to adjust to the situations. I have not—full disclosure—reviewed the agreements in detail before coming here. Again, you talked about indemnity, you talked about pricing and you talked about trade secrets.

Public Accounts committee  We entered into these agreements within the rules of engagement, and I don't think these conversations we're having right now were part of the consideration of the rules of engagement at the time. The context in which these agreements were entered into is very specific. The context in which these contracts were entered into in other countries, with the European Commission and in the U.S., where there was broader support in Moderna's case, are very different.

Public Accounts committee  It won't be a short answer.

Public Accounts committee  That's a very good question. I can no longer remember who it was, but someone mentioned that we had learned many lessons from the pandemic. I think it was Ms. Sinclair-Desgagné. I met with elected representatives so that we could take stock of the lessons learned from the pandemic.

Public Accounts committee  I was not a member of the initial team that negotiated the first contract, which was used as a basis for all the other contracts. I don't know if they were aware. I was only involved in the contracts that were amended and that added…

Public Accounts committee  Honestly, that was neither the focus of my negotiations, nor something that I had thought about. I am telling you that frankly. There was so much happening at the time that it wasn't at the top of the priority list.

Public Accounts committee  I just heard of the bill today. I have not had time to read it, but I can say that, in terms of governance, whistle-blowers and protecting people raising issues is very much aligned with the values of Moderna. I look forward to reading the bill and having further conversations.

Public Accounts committee  Thank you for your question. I must say that the past two years went by as if we were in a fog. That's what happens when you are single-handedly running a business and supplying millions of vaccine doses to Canada. I honestly can't even remember what happened during that period.

Public Accounts committee  This is a hypothetical question, so it's quite hard to answer. What I can say is that the safeguards we have in the agreements have allowed us to focus on bringing doses of vaccines to Canadians. On December 24, 2020, we had 168,000 doses landing at Pearson just on time for Christmas, before when we were planning for.

Public Accounts committee  What I can say is that Canada is getting the first mRNA manufacturing site—

Public Accounts committee  —from Moderna—